R-GLP3 — Research Protocol

Quickstart Highlights

R-GLP3 (Retatrutide) is supplied as a lyophilized powder for laboratory research. Prior to research use, the powder is commonly reconstituted with an appropriate sterile diluent using aseptic laboratory technique. Reconstitution procedures should follow the specific research protocol.

Typical Dose Range
No established or approved dosing regimen exists. Retatrutide remains an investigational compound and dosing has not been established for clinical use.

Easy Measuring Note
The final solution concentration depends on the amount of diluent used during reconstitution. Researchers should calculate concentrations according to their study protocol.

Storage 

• Store unreconstituted vials refrigerated (2–8°C / 36–46°F).
• Protect from excessive heat and direct light.
• After reconstitution, store according to validated laboratory protocol.
• Do not use if the solution appears cloudy, discolored, or contains visible particles.

Dosing & Reconstitution Guide

A 10 mg vial reconstituted with bacteriostatic water yields about 10.0 mg/mL. This information is for research and educational use only.

• Reconstitute: Add 1.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
• Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).

A 30 mg vial reconstituted with bacteriostatic water yields about 10.0 mg/mL. This information is for research and educational use only.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
• Typical weekly range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).

These are only recommended doses,

Supplies Needed

• Bacteriostatic Water (if compatible with your research protocol)
• Sterile syringes
• Alcohol prep swabs
• Lyophilized R-GLP3 vial(s)
• Sharps disposal container
• Appropriate PPE for laboratory handling

Protocol Overview

R-GLP3 (Retatrutide) is a synthetic investigational peptide studied for its activity at the GLP-1, GIP, and glucagon receptors. Current research is evaluating its effects on metabolic regulation, energy expenditure, body weight, and glucose homeostasis.

The compound is supplied as a lyophilized powder and is intended to be reconstituted using sterile laboratory technique before use in research settings.

How It Works

Retatrutide is a triple receptor agonist designed to activate:

• GLP-1 receptors, which influence appetite regulation, gastric emptying, and insulin secretion.
• GIP receptors, which are involved in glucose regulation and metabolic signaling.
• Glucagon receptors, which may increase energy expenditure and affect lipid metabolism.

The combined activation of these pathways is being investigated for potential effects on body weight, glycemic control, and overall metabolic function.

Potential Benefits & Side Effects

Current research is evaluating R-GLP3 for its potential to:

• Support reductions in body weight
• Influence appetite and satiety signaling
• Improve markers of glucose regulation
• Affect lipid metabolism
• Increase energy expenditure
• Provide broader metabolic effects through triple-receptor activity

Safety

R-GLP3 is an investigational compound. Its safety and efficacy have not been established outside controlled clinical research. Adverse events reported in clinical studies have commonly included gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and decreased appetite.

Injection Technique

R-GLP3 is supplied as a lyophilized research compound. Preparation and handling should be performed using sterile laboratory technique in accordance with the applicable research protocol. Researchers should follow their institution’s procedures for preparation, administration, and disposal of investigational materials.